INF7TAT -P55 acetate (P55 acetate) is a polypeptide derived from INF7TAT with G1K, G20L and Y22N mutations. INF7TAT -P55 acetate serves as a delivery carrier to deliver preassembled CRISPR ribonucleases into cells for genome editing [1].
In Vitro, INF7TAT-P55 (peptide/RNP molar ratio 10:1; 1 h) acetate enables efficient, gentle peptide-mediated CRISPR RNP delivery with improved editing rates in primary human CD34+ HSPCs and high edited cell yields in primary human T cells, supporting multiple genome editing applications while preserving cell health[1].
References:
[1]. Sahu SU, et al. Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. Nat Protoc. 2025;20(10):2735-2770.
In Vitro, INF7TAT-P55 (peptide/RNP molar ratio 10:1; 1 h) acetate enables efficient, gentle peptide-mediated CRISPR RNP delivery with improved editing rates in primary human CD34+ HSPCs and high edited cell yields in primary human T cells, supporting multiple genome editing applications while preserving cell health[1].
References:
[1]. Sahu SU, et al. Peptide-enabled ribonucleoprotein delivery for CRISPR engineering (PERC) in primary human immune cells and hematopoietic stem cells. Nat Protoc. 2025;20(10):2735-2770.